[Treatment of lung metastases from malignant melanoma with IL-2 inhalation therapy].
Seven patients with pulmonary metastases of malignant melanoma were treated with inhalation therapy with 36 million IU interleukin-2 for six months. Inhalation therapy was combined with four bolus infusions of DTIC at a dose of 850 mg/m2 once every four weeks. Response rates were 71.4% with 2 patients achieving a complete remission (CR), 2 partial remissions (PR), 1 stable disease (SD), and 2 progressing disease (PD). Therapy was well tolerated with low toxicity. Six of the patients developed cough; one patient was slightly feverish. We conclude that inhalation therapy of lung metastases is a promising addition to the therapeutic arsenal against malignant melanoma.
Enk
A H
AH
Univ.-Hautklinik Mainz.
Nashan
D
D
Knop
J
J
D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018664:Interleukin-12 / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
D018664:Interleukin-12; D003606:Dacarbazine
Therapie von Lungenmetastasen des malignen Melanoms mit inhalativem IL-2.